Who
Lawrence Otto Klein
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Oruka Therapeutics; Director, Jade Biosciences; Director, Jasper Therapeutics; Cbo & COO, CRISPR Therapeutics AG; Director, Dyne Therapeutics.
In numbers
- Trades disclosed
- 125
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $42.7M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 2 Jan 2019
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $195K25,000 at $7.80 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M16,246 at $83.40 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $719K8,554 at $84.03 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K200 at $84.78 | filing |
| 1 Oct 2026filed 2 Oct 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $235K2,452 at $95.71 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $235K2,452 at $95.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $585K75,000 at $7.80 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $600K6,604 at $90.79 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.8M63,596 at $91.90 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —75,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $444K4,800 at $92.44 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —75,000 at $0.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $585K75,000 at $7.80 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $600K6,604 at $90.79 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.8M63,596 at $91.90 | filing |
| 1 Sep 2026filed 1 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $444K4,800 at $92.44 | filing |
| 15 Jun 2026filed 15 Jun 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $120K1,729 at $69.69 | filing |
| 15 Jun 2026filed 15 Jun 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $120K1,729 at $69.69 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
News
Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 2,452 Sharesthemarketsdaily.com · 16 Sep 2026
1 headline in the last 90 days name Lawrence Otto Klein; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.